Analysts Are Bullish on Top Healthcare Stocks: Thermo Fisher (TMO), Intra-Cellular Therapies (ITCI)

Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success

Analysts Conflicted on These Healthcare Names: Intra-Cellular Therapies (ITCI), Eli Lilly & Co (LLY) and Sanofi (OtherSNYNF)

Intra-Cellular Therapies Prices Public Offering of Common Stock

Biotech Leader Intra-Cellular Soars 23%, Breaks Out Past Latest Buy Point

Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals

Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals

Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?

Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and Intra-Cellular Therapies (ITCI)

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

Intra-Cellular Launches 23% To Record High, Breaking Out After Depression Drug Scores Big

Drugmaker Intra-Cellular Soars as Depression Trial Succeeds

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Intra-Cellular Therapies (ITCI)

Intra-Cellular builds case for depression drug with late-stage trial win

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Intra-Cellular Therapies (NASDAQ:ITCI) advances 6.5% this week, taking five-year gains to 467%

Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes

Intra-Cellular Therapies Inc Chairman, President & CEO Sharon Mates Sells 61,277 Shares

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences